Metropolis Healthcare Limited

BSE: 542650 NSE: METROPOLIS
Metropolis Healthcare Limited - healthcare in Mumbai, Maharashtra, India. FY 2026 financials & compliance.
CIN L73100MH2000PLC192798 Incorporated 10 November 2000 ROC Mumbai HQ Mumbai, Maharashtra, India
Active Listed - NSE: METROPOLIS · BSE: 542650 Public Limited Company healthcare BSE 500
Data last updated
Market Cap
₹12,063 Cr
METROPOLIS · NSE
Share Price
₹571.00
-1.76% today
Revenue
₹1,646 Cr
FY 2025-26 · +23.6% YoY
EBITDA
₹396 Cr
Margin 24.1%
Net Profit
₹194 Cr
FY 2025-26 · +42.3% YoY
P/E (TTM)
55.8x
P/B 7.7x
ROE
13.4%
ROCE 17.2%
Debt / Equity
0.15
Interest cover 11.0x

About Metropolis Healthcare Limited

Data last updated:

Metropolis Healthcare Limited is a public limited company based in Mumbai, Maharashtra, India. It operates in the diagnostic centers and pathology labs segment of the healthcare sector. It was incorporated on 10 November 2000 and has been in existence for over 26 years.

Metropolis Healthcare is part of the BSE 500 index. Its director Sushil Shah and family are #530 among India's richest people (2026).

The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN L73100MH2000PLC192798. Its GSTIN is 06AACCP1414E1Z1 (Haryana). The company holds 4 GST registrations, of which 1 is active. It is a listed company as per MCA records. Its shares are listed on BSE: 542650 and NSE: METROPOLIS.

The company has an authorised share capital of ₹63.86 Cr and a paid-up capital of ₹41.49 Cr. It was formerly known as Articles of Association of Metropolis Healthcare Limited and Pathnet India Limited. It is led by directors including Chemmenkotil Surendran (Managing Director) and Ameera Sushil Shah (Whole-Time Director).

Its last annual general meeting (AGM) was held on 18 August 2026, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Mumbai, Maharashtra.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹1,645.85 Cr, a growth of 23.6% compared to the previous year. For the same year it recorded a net profit of ₹193.92 Cr (net margin 11.8%) and EBITDA of ₹396.22 Cr (EBITDA margin 24.1%). The net worth stands at ₹1,513.16 Cr (up 13.7% YoY). Total assets are valued at ₹1,792.05 Cr (up 14.5% YoY).

The company has about 4,503 employees on its provident fund (EPFO) records. Its group structure includes 4 subsidiaries.

The company is associated with 3 brands: Too Shy To Ask, Hitech and Metropolis India. As per MCA filings, the company has open charges of ₹60.19 Cr and satisfied charges of ₹416.05 Cr on record. Court records list 159 cases involving the company, including 128 filed by the company and 31 filed against it; 21 cases are pending. The company has 32 deals on record (15 market trades, 12 secondary share transfers, 4 funding rounds), with disclosed funding of ₹169.77 Cr; the latest was in December 2025. Its 3 peer companies in the Healthcare industry (Diagnostics and Pathology Labs), with the same principal business activity (medical and dental practice, nursing, pathology, blood bank services, etc.) are compared by revenue, 1 larger and 2 smaller; the largest is Dr. Lal Pathlabs Limited with revenue of ₹2,554.83 Cr. The company has 7 MSME Form 1 returns on record between 2020 and 2022, listing 749 overdue payments to 60 micro and small suppliers.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website metropolisindia.com.

Company details

CIN L73100MH2000PLC192798
Registration Number 192798
Incorporation Date 10 November 2000
ROC Mumbai
Listing Status Listed - Listed on NSE (METROPOLIS); Listed on BSE (542650)
Company Status Active
Date of Last AGM 18 August 2026
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant

Name history

Metropolis Healthcare has undergone 4 name changes throughout its history. The current legal name is Metropolis Healthcare Limited.

Company NameStatus
Metropolis Healthcare LimitedCurrent
Articles Of Association Of Metropolis Healthcare LimitedPrevious
Pathnet India LimitedPrevious
Pathnet India Private LimitedPrevious
Pathnet India LimitedPrevious

CIN history

Metropolis Healthcare has 3 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L73100MH2000PLC192798, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L73100MH2000PLC192798Current
U73100MH2000PLC192798Previous
U73100MH2000PTC192798Previous
U73100DL2000PTC108483Previous
Key People
Chemmenkotil Surendran Managing Director Ameera Sushil Shah Whole-Time Director Sushil Kanubhai Shah Director

Recognitions & Rankings of Metropolis Healthcare

India's Most Valuable Companies 2024 edition · Source: Hurun India
Rank#438
Valuation
₹11,210 Cr
2023 #488 2022 #369 2021 #246
India's Richest People 2026 edition · 1 director · Source: Hurun India
Stock market indices
BSE 500

Contact details

Metropolis Healthcare Limited's registered office is in Mumbai, Maharashtra. Its website is metropolisindia.com. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Website
    metropolisindia.com
  • Social Media
  • Apps
  • Registered Address
    4th Floor East Wing Plot – 254 B, Nirlon House Dr. Annie Besant Road Worli, Mumbai, Maharashtra, India – 400030
  • Industry
    Healthcare, Diagnostic Centers & Pathology Labs

To see the full contact details of Metropolis Healthcare Limited, buy the company report.

Comprehensive company report
Metropolis Healthcare Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Metropolis Healthcare operates multiple associated brands including Too Shy To Ask, HITECH, and Metropolis India. Each brand links to its own profile.

BrandDescriptionWebsite
Too Shy To Ask
Provides online education on sexual health, mental health, and personal safety for teens and parents.tooshytoask.org
HITECH
Chain of diversified clinical laboratory centershitechlabsindia.in
Metropolis India
Diagnostic centers are operated as a nationwide chain.metropolisindia.com

Business activity

The main business activity of Metropolis Healthcare is hospital and medical care. In detail, this covers medical and dental practice, nursing, pathology, blood bank services, etc..

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
QHospital and Medical CareQ2Medical and dental practice, Nursing, pathology, blood bank services, etc.

To see the full business activity and turnover split of Metropolis Healthcare Limited, buy the company report.

Financials of Metropolis Healthcare Limited

FY 2025-26 filings available

Metropolis Healthcare Limited reported revenue of ₹1,645.85 Cr (up 23.6% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹1,646 Cr
+23.6% YoY
EBITDA
₹396 Cr
+28.5% YoY
Profit After Tax
₹194 Cr
+42.3% YoY
Net Worth
₹1,513 Cr
+13.7% YoY
Total Assets
₹1,792 Cr
+14.5% YoY
Total Debt
₹232 Cr
+13.6% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue1,6461,3311,2081,1481,228998856
Revenue growth+23.6%+10.2%+5.2%-6.5%+23.1%+16.5%-
EBITDA396308288293348290212
EBITDA margin+24.1%+23.2%+23.8%+25.6%+28.3%+29.0%+24.8%
Profit before tax259191175188293244169
Net profit194136127143203183144
Net profit margin+11.8%+10.2%+10.5%+12.4%+16.5%+18.3%+16.8%
EPS (₹)9.1727.9924.9527.9041.8635.8225.15
Balance sheet
Total assets1,7921,5661,3121,2711,279830602
Net worth1,5131,3311,096988886707524
Total debt23220419726637911266.70
Cash & bank62.3249.0271.2293.19167420210
Net working capital87.5974.4394.88137215430236
Cash flow
Cash from operations351263264247253249215
Cash from investing(220)(199)(89.09)48.09(736)63.08(104)
Cash from financing(115)(86.63)(181)(292)163(32.69)(55.32)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue450425406429386345323350
Revenue growth (YoY)+16.6%+23.0%+25.8%+22.7%+23.2%---
Other income5.108.279.020.897.526.972.563.13
EBITDA11110885.7510889.7562.2972.0189.88
EBITDA margin+24.7%+25.4%+21.1%+25.2%+23.2%+18.0%+22.3%+25.7%
Depreciation32.4038.5931.8832.4130.8528.6227.7026.82
Interest6.187.935.735.685.204.604.534.79
Profit before tax77.7269.7757.1671.0261.2236.0442.3461.40
Tax20.8318.8015.0718.1315.986.8210.8614.70
Net profit56.8950.9742.0952.8945.2429.2231.4846.70
EPS (₹)2.732.467.9410.138.665.666.099.03
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue1,3651,2161,1031,0661,157816665
Revenue growth+12.3%+10.2%+3.5%-7.9%+41.8%+22.7%-
EBITDA334272263274324242152
EBITDA margin+24.5%+22.4%+23.9%+25.7%+28.0%+29.7%+22.8%
Profit before tax212162157179272246140
Net profit161116115139188198130
Net profit margin+11.8%+9.6%+10.4%+13.0%+16.2%+24.2%+19.5%
EPS (₹)7.6024.0922.6227.1338.9938.6522.13
Balance sheet
Total assets1,6021,4461,2421,2171,229801572
Net worth1,3891,2441,031936839709512
Total debt18217819526837784.9753.54
Cash & bank20.5525.5230.4642.94115335132
Net working capital9.7122.1661.97112189384185
Cash flow
Cash from operations318273269238244202156
Cash from investing(209)(194)(81.51)46.72(736)73.53(51.13)
Cash from financing(111)(84.50)(183)(288)172(26.33)(46.37)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue372352335356324312297322
Revenue growth (YoY)+15.0%+12.9%+12.7%+10.6%+13.1%---
Other income5.198.822.222.522.787.763.033.59
Total expenses279262263264247259232240
EBITDA93.6990.1372.1991.3577.0552.5265.1082.02
EBITDA margin+25.2%+25.6%+21.6%+25.7%+23.8%+16.9%+21.9%+25.5%
Depreciation27.8132.8027.7227.7927.8627.2726.8526.01
Interest4.776.564.373.974.294.434.494.73
Profit before tax66.3059.5942.3262.1147.6828.5836.7954.87
Tax15.7216.3510.2915.4812.104.739.3912.61

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 05 Nov 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue450425406429386345323350
Revenue growth (YoY)+16.6%+23.0%+25.8%+22.7%+23.2%---
Other income5.108.279.020.897.526.972.563.13
EBITDA11110885.7510889.7562.2972.0189.88
EBITDA margin+24.7%+25.4%+21.1%+25.2%+23.2%+18.0%+22.3%+25.7%
Depreciation32.4038.5931.8832.4130.8528.6227.7026.82
Interest6.187.935.735.685.204.604.534.79
Profit before tax77.7269.7757.1671.0261.2236.0442.3461.40
Tax20.8318.8015.0718.1315.986.8210.8614.70
Net profit56.8950.9742.0952.8945.2429.2231.4846.70
EPS (₹)2.732.467.9410.138.665.666.099.03
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue1,6461,3311,2081,1481,228998856
Revenue growth+23.6%+10.2%+5.2%-6.5%+23.1%+16.5%-
Other income25.5815.119.1215.2233.6212.058.57
Total expenses1,2501,023920855880708644
Employee cost377314276253233199190
EBITDA396308288293348290212
EBITDA margin+24.1%+23.2%+23.8%+25.6%+28.3%+29.0%+24.8%
Depreciation13410994.4789.2263.2245.9439.27
Interest28.9023.8927.8931.8525.0211.5612.65
Profit before tax259191175188293244169
Tax67.9945.3446.2344.1178.6660.9741.18
Net profit194136127143203183144
Net profit margin+11.8%+10.2%+10.5%+12.4%+16.5%+18.3%+16.8%
EPS (₹)9.1727.9924.9527.9041.8635.8225.15
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital41.4710.3610.2510.2410.2310.2210.13
Reserves & surplus1,4611,3131,078978876696513
Shareholders' funds (net worth)1,5131,3311,096988886707524
Minority interest11.393.673.122.481.971.461.66
Secured loans18.7314.190.0079.052590.000.00
Unsecured loans21319019718712011266.70
Total debt23220419726637911266.70
Total liabilities1,7921,5661,3121,2711,279830602
Assets
Gross block1,9011,6971,3821,2961,192438366
Net block1,6011,4471,1771,1211,059343296
Capital work in progress0.000.000.0019.515.780.002.99
Investments14271.0054.8314.8115.5110.0814.32
Inventories45.4947.8438.6944.5951.1140.5524.40
Sundry debtors170148126122135123128
Cash & bank balances62.3249.0271.2293.19167420210
Loans & advances49.8731.8926.5730.0025.8416.9121.37
Total current assets328277263290379600384
Total current liabilities240202168153164171149
Net working capital87.5974.4394.88137215430236
Total assets1,7921,5661,3121,2711,279830602
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash39.4862.6268.8365.9838710751.37
Net cash from operating activities351263264247253249215
Net cash from investing activities(220)(199)(89.09)48.09(736)63.08(104)
Net cash from financing activities(115)(86.63)(181)(292)163(32.69)(55.32)
Net change in cash15.31(23.14)(6.21)2.85(321)27955.80
Closing cash62.3249.0271.2293.19167420210
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+23.6%+10.2%+5.2%-6.5%+23.1%+16.5%-
EBITDA growth+28.5%+7.1%-1.9%-15.7%+20.1%+36.6%-
PBT growth+35.8%+9.3%-6.8%-36.1%+20.1%+44.8%-9.6%
Net income growth+42.3%+7.2%-11.0%-29.5%+10.9%+27.0%-
Revenue CAGR (3Y)+12.8%+2.7%+6.6%+10.3%+17.3%+15.5%+16.3%
EBITDA CAGR (3Y)+10.5%-4.0%-0.2%+11.4%+19.8%+17.5%+11.4%
Profitability & leverage
Net income margin+11.6%+10.9%+10.6%+12.5%+17.5%+18.4%+14.9%
Return on capital employed+17.2%+15.0%+15.7%+17.2%+30.2%+35.8%+39.5%
Return on net worth+13.4%+12.0%+12.3%+15.3%+27.0%+29.8%+30.6%
Debt / equity0.150.170.220.340.310.150.09
Long-term debt / equity0.090.100.130.210.200.110.05
Interest cover11.0111.9714.4215.608.794.747.32
Efficiency & per share
Fixed asset turnover0.910.860.900.921.512.482.69
Inventory turnover35.2730.7729.0024.0026.8030.7333.92
Debtors turnover10.349.719.738.929.507.946.46
EPS (₹)9.1727.9924.9527.9041.8635.8225.15
Dividend per share (₹)5.000.004.008.008.008.008.00
Book value per share (₹)72.46255.41212.47192.97173.18138.23103.40
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue372352335356324312297322
Revenue growth (YoY)+15.0%+12.9%+12.7%+10.6%+13.1%---
Other income5.198.822.222.522.787.763.033.59
Total expenses279262263264247259232240
EBITDA93.6990.1372.1991.3577.0552.5265.1082.02
EBITDA margin+25.2%+25.6%+21.6%+25.7%+23.8%+16.9%+21.9%+25.5%
Depreciation27.8132.8027.7227.7927.8627.2726.8526.01
Interest4.776.564.373.974.294.434.494.73
Profit before tax66.3059.5942.3262.1147.6828.5836.7954.87
Tax15.7216.3510.2915.4812.104.739.3912.61
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue1,3651,2161,1031,0661,157816665
Revenue growth+12.3%+10.2%+3.5%-7.9%+41.8%+22.7%-
Other income16.6717.5012.0021.2832.1548.6529.32
Total expenses1,032944840792833574514
Employee cost297272247228218157148
EBITDA334272263274324242152
EBITDA margin+24.5%+22.4%+23.9%+25.7%+28.0%+29.7%+22.8%
Depreciation11610590.7384.9660.2636.2030.85
Interest22.8022.9927.2531.2924.548.7510.01
Profit before tax212162157179272246140
Tax54.1137.0741.5240.0072.0148.4927.93
Net profit161116115139188198130
Net profit margin+11.8%+9.6%+10.4%+13.0%+16.2%+24.2%+19.5%
EPS (₹)7.6024.0922.6227.1338.9938.6522.13
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital41.4710.3610.2510.2410.2310.2210.13
Reserves & surplus1,3371,2261,013926829699502
Shareholders' funds (net worth)1,3891,2441,031936839709512
Secured loans0.000.000.0079.052590.000.00
Unsecured loans18217819518911984.9753.54
Total debt18217819526837784.9753.54
Total liabilities1,6021,4461,2421,2171,229801572
Assets
Gross block1,3921,3461,3131,2291,131321265
Net block1,1351,1291,1201,0661,005251216
Capital work in progress0.000.000.0019.515.780.002.99
Investments48432189.7349.7150.41131130
Inventories32.2131.5533.8941.2747.0133.4617.46
Sundry debtors119114130126140123124
Cash & bank balances20.5525.5230.4642.94115335132
Loans & advances39.8119.7824.9841.9636.5924.8128.21
Total current assets211191219252339516302
Total current liabilities202168157140150132117
Net working capital9.7122.1661.97112189384185
Total assets1,6021,4461,2421,2171,229801572
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash22.6828.5924.0927.4934867.438.80
Net cash from operating activities318273269238244202156
Net cash from investing activities(209)(194)(81.51)46.72(736)73.53(51.13)
Net cash from financing activities(111)(84.50)(183)(288)172(26.33)(46.37)
Net change in cash(2.62)(5.90)4.50(3.40)(320)25058.63
Closing cash20.5525.5230.4642.94115335132
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+12.3%+10.2%+3.5%-7.9%+41.8%+22.7%-
EBITDA growth+22.6%+3.4%-3.8%-15.5%+33.8%+60.0%-
PBT growth+30.7%+2.8%-12.0%-34.1%+10.4%+75.8%-6.2%
Net income growth+38.3%+0.9%-17.1%-26.1%-4.9%+52.3%-
Revenue CAGR (3Y)+8.6%+1.7%+10.6%+17.0%+25.8%+19.0%+18.0%
EBITDA CAGR (3Y)+6.8%-5.7%+2.8%+21.8%+30.0%+21.1%+7.8%
Profitability & leverage
Net income margin+11.5%+10.3%+10.5%+13.0%+17.3%+24.2%+16.8%
Return on capital employed+15.4%+13.8%+15.0%+17.2%+29.2%+37.1%+34.6%
Return on net worth+12.0%+11.0%+11.8%+15.7%+25.8%+32.4%+28.0%
Debt / equity0.140.160.240.360.300.110.08
Long-term debt / equity0.080.100.140.220.190.080.04
Interest cover10.4713.7415.7816.569.304.248.30
Efficiency & per share
Fixed asset turnover1.000.910.870.901.592.782.83
Inventory turnover42.8337.1629.3624.1528.7632.0535.86
Debtors turnover11.749.988.618.008.796.615.48
EPS (₹)7.6024.0922.6227.1338.9938.6522.13
Dividend per share (₹)5.000.004.008.008.008.008.00
Book value per share (₹)66.47238.71199.79182.78164.00138.69101.20

To see the full year-wise statements and ratios of Metropolis Healthcare Limited, buy the company report.

Board of directors of Metropolis Healthcare Limited

Metropolis Healthcare has 10 current directors and 28 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Ameera Sushil Shah
Also directs: Aaranya Spaces LLP, Metz Advisory LLP, G&L Advisory LLP and 4 more
Whole-Time Director06 May 200818 Years 5 MonthsCurrent
Sushil Kanubhai Shah
Also directs: Aaranya Spaces LLP, Nitrolabs Technology Private Limited
Director17 Aug 200521 Years 2 MonthsCurrent
Hemant Sachdev
Also directs: G&L Advisory LLP, Nexus Nextgen Works LLP, Singer India Limited and 5 more
Director27 May 20215 Years 5 MonthsCurrent
Vivek Gambhir
Also directs: Imagine Marketing Limited, Honasa Consumer Limited, Hob Ventures Private Limited and 4 more
Director07 Sep 20188 Years 1 MonthsCurrent
Sanjay Bhatnagar
Also directs: Eih Limited, Bhatnagar Estates Private Limited, Thot Global Strategies Private Limited
Director07 Sep 20188 Years 1 MonthsCurrent
Chemmenkotil Surendran
Also directs: Metropolis Quality Solutions Private Limited, Core Diagnostics Private Limited, Metropolis Foundation
Managing Director01 Jun 20251 Years 5 MonthsCurrent
Showing 6 of 10 current directors. View all directors

Peer comparison

Metropolis Healthcare Limited is compared with the 3 companies closest to it by revenue in the Healthcare industry (Diagnostics and Pathology Labs), with the same principal business activity (medical and dental practice, nursing, pathology, blood bank services, etc.), from the latest filed financials of each company.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Dr. Lal Pathlabs Limited₹2,554.83 Cr (FY 2025)11.0%New Delhi, Delhi, India
Metropolis Healthcare Limitedthis company₹1,645.85 Cr (FY 2026)₹193.92 Cr11.8%23.6%4,503Mumbai, Maharashtra, India
Neuberg Diagnostics Private Limited₹853.26 Cr (FY 2025)13.0%Chennai, Tamil Nadu, India
Vijaya Diagnostic Centre Limited₹699.71 Cr (FY 2025)23.0%Hyderabad, Telangana, India

To see the full peer comparison of Metropolis Healthcare Limited, buy the company report.

Auditor

Metropolis Healthcare Limited is audited by B S R & Co. LLP for the financial year 2023.

Auditor firmFinancial yearFirm registration number
B S R & Co. LLPFY 2023101248W/W-100022

Shareholding

Shareholding for the quarter ended Sep 2026: promoters hold 48.90%, foreign institutional investors hold 11.00%, domestic institutional investors hold 35.20% and retail and other public shareholders hold 5.00%.

Promoters: 48.90%DII (Domestic Institutional): 35.20%FII (Foreign Institutional): 11.00%Retail & Others: 5.00%
Sep 2026
QUARTER
48.90% Promoters
35.20% DII (Domestic Institutional)
11.00% FII (Foreign Institutional)
5.00% Retail & Others
Promoter holding - history
Now 48.90% · Sep 2026High 48.90% · Dec 2025Low 48.90% · Dec 2025
47%47.8%48.5%49.3%50%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 48.90%Mar 2026: 48.90%Jun 2026: 48.90%Sep 2026: 48.90%48.90%48.90%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters48.90%48.90%48.90%48.90%
Public51.10%51.10%51.10%51.10%

Charges & borrowings

Open charges
₹60.19 Cr
Satisfied charges
₹416.05 Cr
Breakdown by lending institutions
Others₹30.00 Cr
Hdfc Bank Limited₹30.00 Cr
Icici Bank Limited₹0.12 Cr
Textile Trafers Co-Op. Bank₹0.07 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
19 Jun 2025101122027Others₹30 CrOpen
09 Jun 200810115113Hdfc Bank Limited₹30 CrOpen
31 May 200710056644Icici Bank Limited₹11.65 LakhOpen
03 Nov 199790112396Textile Trafers Co-Op. Bank₹7 LakhOpen
07 Apr 2022100566117Hdfc Bank Limited₹150 CrSatisfied

To see the full charge records of Metropolis Healthcare Limited, buy the company report.

Total charge records: 17 View all charges

Deals & funding

Metropolis Healthcare Limited has 32 deals on record (15 market trades, 12 secondary share transfers, 4 funding rounds), with disclosed funding of ₹169.77 Cr; the latest was in December 2025.

Total deals
32
Market trades
15
Secondary share transfers
12
Funding rounds
4
IPO
1
Disclosed funding
₹169.77 Cr

Deals on record (5 of 32)

WhenDealAmountParties
Dec 2023Market trade₹47.28 CrBuyer: Graviton Research Capital LLP
Seller: Graviton Research Capital LLP
Jul 2020Secondary share transferUndisclosedBuyer: Icici Prudential Mutual Fund, Birla Sun Life Mutual Fund, Aditya Birla Sun Life Mutual Fund
Seller: The Carlyle Group
Jul 2020Market trade₹168.46 CrBuyer: Icici Prudential Mutual Fund, Birla Sun Life Mutual Fund, Aditya Birla Sun Life Mutul Fund
Seller: The Carlyle Group
Apr 2020Market trade₹763.54 CrBuyer: Smallcap World Fund Inc, Millennium Stock Broking Private Limited , Marwadi Shares and Finance Limited
Seller: The Carlyle Group, Millennium Stock Broking Private Limited , Marwadi Shares and Finance Limited
Apr 2020Market trade₹82.19 CrBuyer: Millennium Stock Broking Private Limited , Marwadi Shares and Finance Limited
Seller: Millennium Stock Broking Private Limited , Marwadi Shares and Finance Limited

To see the full deal history of Metropolis Healthcare Limited, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

Credit ratings & regulatory alerts

Metropolis Healthcare Limited was last rated by Crisil on 30 Sep 2020.

Rating agencyRated onRating
Crisil30 Sep 2020

To see the full credit ratings and regulatory alerts of Metropolis Healthcare Limited, buy the company report.

MSME payment delays

Metropolis Healthcare Limited has 7 MSME Form 1 returns on record between 2020 and 2022, listing 749 overdue payments to 60 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 60)

SupplierAmount dueDue sinceReported on
R. K. Diagnostics
an individual supplier
an individual supplier
an individual supplier
CPC Diagnostics Private Limited

To see the full MSME payment records of Metropolis Healthcare Limited, buy the company report.

Individuals and sole proprietors among the suppliers are not named.

Group structure & subsidiaries

Metropolis Healthcare has 4 subsidiary companies. This group structure data is as of FY 2023. The table lists each entity with its relationship and holding.

4
Subsidiary companies
Key subsidiaries
Company NameCINShares held
Amin's Pathology Laboratory Private LimitedU52300MH2012PTC236779
Centralab Healthcare Services Private LimitedU85110KA2011PTC057920
Metropolis Histoxpert Digital Services Private LimitedU85320MH2018PTC304941
Ekopath Metropolis Lab Services Private LimitedU93000MH2013PTC240481

To see the full group structure of Metropolis Healthcare Limited, buy the company report.

Employees & EPFO

Metropolis Healthcare Limited has a workforce of 4,503 employees on its EPFO records as of Apr 04, 2024, across 6 active EPFO establishments.

Employee count
4,503
Active EPFO establishments
6
Employee growth
14.9%

GST

Metropolis Healthcare has 4 GST registrations: 1 active and 3 cancelled or inactive.

Total GSTINs
4
Active
1
Cancelled / inactive
3
GSTINStateStatusRegistered on
06AACCP1414E1Z1HaryanaActive01 Aug 2017

To see the full GST registrations and return filing status of Metropolis Healthcare Limited, buy the company report.

Recent activity

Metropolis Healthcare Limited has 53 board changes on record since 2005: 32 appointments and 21 cessations. The latest: Chemmenkotil Surendran was appointed as Managing Director on 01 Jun 2025.

AGM
Metropolis Healthcare Limited last Annual general meeting of members was held on 18 Aug 2026 as per latest MCA records.
Filing
Metropolis Healthcare Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Mumbai I.
Charges
A charge with Others amounted to Rs. 30.00 Cr with Charge ID 101122027 was registered on 19 Jun 2025.
Appointed
Chemmenkotil Surendran was appointed as Managing Director.
Appointed
Rehan Khan Abbas was appointed as Director.
Ceased
Anita Ramachandran ceased to be Director.
Appointed
Purvi Sheth was appointed as Director.
Appointed
Sameer Prakash Patel was appointed as CFO.
Ceased
Aditya Vijay Shinde ceased to be CFO.
Appointed
Aditya Vijay Shinde was appointed as CFO.
Ceased
Rakesh Agarwal ceased to be CFO.
Appointed
Aparna Chetan Rajadhyaksha was appointed as Director.

78 earlier events are in the company report.

News

Metropolis: Co Raises Lab Enhancement Outlook, Expecting 46% Boost in Lab Use by FY29 and Plan Price Increases in Q4 FY27 to Drive Higher Revenue and Margin Growth.
04 Nov 2026 · Exchange Update
Metropolis: Co Guides For 120-170 Bps EBITDA Margin Expansion In Fy27, Backed By Planned Q4 B2C Price Hike And Lab Platform Completion
04 Nov 2026 · Exchange Update
METROPOLIS: Q2 REVENUE 4.97B RUPEES VS 4.3B (YOY)
03 Nov 2026 · Exchange Update
METROPOLIS: Q2 CONS NET PROFIT 753M RUPEES VS 527M (YOY)
03 Nov 2026 · Exchange Update
METROPOLIS: Q2 EBITDA 1.34B RUPEES VS 1.1B (YOY); Q2 EBITDA MARGIN 26.96% VS 25.22% (YOY)
03 Nov 2026 · Exchange Update
Metropolis Healthcare: Q2 FY27 Revenue Rises 15% Year-Over-Year Due To Strong Patient And Test Volume Growth, EBITDA Margins Increase.
05 Oct 2026 · Exchange Update

Frequently asked questions

Metropolis Healthcare is an active public limited company based in Mumbai, Maharashtra, India. The company works in diagnostic centers and pathology labs, within the healthcare industry. It was incorporated on 10 November 2000 (26+ years old) and is registered under CIN L73100MH2000PLC192798. Listed on BSE: 542650 and NSE: METROPOLIS.

Metropolis Healthcare reported revenue of ₹1,645.85 Cr for FY 2025-26 (up 23.6% YoY) based on consolidated financials.

Metropolis Healthcare has 10 current directors:

The latest financial statements of Metropolis Healthcare on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 18 August 2026. Year-wise statements from 2015 are in the company report.

The GSTIN of Metropolis Healthcare is 06AACCP1414E1Z1, registered in Haryana. The company has 4 GST registrations in all, of which 1 is active and 3 are cancelled or inactive.

The CIN (Corporate Identification Number) of Metropolis Healthcare is L73100MH2000PLC192798. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Metropolis Healthcare is a listed company as per MCA records. Its shares are listed on both BSE (code: 542650) and NSE (symbol: METROPOLIS).

Metropolis Healthcare has 159 court cases on record: 128 filed by the company and 31 filed against it. 21 are pending. Most are in the district courts.

Metropolis Healthcare was incorporated on 10 November 2000, making it 26+ years old. It is registered with the Registrar of Companies, Mumbai.

Metropolis Healthcare has 32 deals on record (15 market trades, 12 secondary share transfers, 4 funding rounds), with disclosed funding of ₹169.77 Cr; the latest was in December 2025.

The peers of Metropolis Healthcare by revenue are Dr. Lal Pathlabs Limited, Neuberg Diagnostics Private Limited, Vijaya Diagnostic Centre Limited, all in the Healthcare industry (Diagnostics and Pathology Labs), with the same principal business activity (medical and dental practice, nursing, pathology, blood bank services, etc.).

Chemmenkotil Surendran was appointed as Managing Director on 01 Jun 2025. Rehan Khan Abbas was appointed as Director on 13 May 2025. Anita Ramachandran ceased to be Director on 17 Mar 2025. Metropolis Healthcare has 53 board changes on record in total.